Abstract and Introduction
The California Technology Assessment Forum (CTAF) was asked to assess the evidence for the use of transcatheter aortic valve replacement for the treatment of patients with aortic stenosis who are not surgical candidates. Aortic stenosis is treated medically until the valve area decreases to a critical point or the patient becomes symptomatic. Because valvular aortic stenosis is primarily a disease of aging, many patients with aortic stenosis have significant co-morbidities that preclude surgical intervention. The FDA recently approved an aortic valve replacement device that can be implanted without requiring a median sternotomy and cardioplegia.
CTAF © 2012 California Technology Assessment Forum